Bayerische Motoren Werke ADR (BMWYY)

The geopolitical landscape was rocked in early 2026 by the so-called "Greenland Episode," a diplomatic and economic confrontation that has pushed the relationship between the United States and the European Union to its lowest point in decades. What began as a renewed U.S. strategic interest in the Arctic territory

In a landmark shift for the robotics industry, Boston Dynamics has officially transitioned its iconic Atlas robot from a research prototype into a fully autonomous, production-ready workforce. Unveiled in its final commercial form at CES 2026, the all-electric Atlas has shed its hydraulic past and "viral stunt" reputation in favor of sophisticated reinforcement learning (RL) [...]

As the first quarter of 2026 unfolds, the financial markets are navigating a paradoxical landscape defined by aggressive fiscal expansion and unprecedented geopolitical friction. While the "Stampeding Bull" of 2024 and 2025 was driven by a frenzy of price-to-earnings expansion and artificial intelligence (AI) hype, a new narrative has taken

On February 6, 2026, the semiconductor landscape witnessed a jarring recalibration as Qualcomm Incorporated (NASDAQ: QCOM) shares plummeted 8.5% in a single trading session. The catalyst for this sharp correction was not a failure of innovation or a loss of market share, but rather a "structural bottleneck" described by management during their Q1 fiscal 2026 [...]

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery to remove a tumor has elicited excitement as it could provide a way forward in eliminating microscopic cancer tissue that surgeons are unable to see while surgically removing a cancerous tumor from the brain.

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA (“ctDNA”), a marker associated with minimal residual disease (“MRD”) and cancer recurrence, with the trial planned to begin in the first half of 2026 under the leadership of Dr. Paula Pohlmann of MD Anderson Cancer Center.

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-active ferrous iron in living cells. The company said the findings extend its previously reported iron-reduction data by demonstrating, for the first time, a coupled intracellular metal-modulating mechanism rather than simple extracellular chelation, supporting a potential upstream approach to addressing oxidative stress, mitochondrial dysfunction, epigenetic instability, and genomic damage associated with cancer and aging.

In the microcap market, capital formation is often synonymous with dilution. Companies raise money by issuing new shares, frequently at the expense of long-term shareholders, creating a cycle where growth in operations does not translate into growth in per-share value. Against that backdrop, capital discipline itself becomes a differentiator, and increasingly, a signal of management intent.

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments under development. The use of this platform promises to significantly reduce the costs and time needed in the drug development process.

Rivian is an innovative EV company making some neat trucks and SUVs, but is it a buy at these prices?

Auto lease services in Feasterville-Trevose have shifted as VIP Auto PA continues to gain recognition for its no-haggle approach to vehicle acquisition. Operating from 2399 Old Lincoln Hwy, the company has been serving Pennsylvania drivers since 2007 with a business model that prioritizes straightforward transactions over traditional dealership tactics.

Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well existing treatments work, rather than introducing entirely new drugs.

LuxuryCars.ng has officially launched a premium online automotive marketplace designed to connect Nigerian buyers with verified sellers of foreign used (Tokunbo) luxury vehicles, introducing a more transparent and structured approach to high-end car transactions nationwide.

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its intranasal concussion therapy ONP-002 toward U.S.-based development, with the engagement intended to align the Company’s upcoming Phase 2a clinical trial in Australia with its U.S. regulatory strategy and support progression toward a future U.S. Phase 2b trial and later-stage development.

According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024 . That figure equates to 18% of GDP, and is double what is spent on average in other developed countries. Americans are feeling the pinch, and an estimated 100 million individuals in the country have medical debt.

Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new burdens. Soligenix (NASDAQ: SNGX) is advancing new treatment approaches focused on improving tolerability and long-term quality of life for patients living with this rare cancer.

The global financial markets are still reeling after a tumultuous January that saw the return of "Twitter-diplomacy" and high-stakes protectionism. Following President Donald Trump’s aggressive mid-month demand for the United States to purchase Greenland, a move punctuated by threats of sweeping tariffs against European allies, the Dow Jones Industrial

VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as

The global financial landscape has been jolted by a profound "Greenland rift" as the United States aggressively asserts its territorial ambitions over the autonomous Danish territory. This geopolitical friction, which reached a fever pitch in January 2026, has pitted Washington against Copenhagen and Brussels, triggering an unprecedented deployment of European

As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and diagnostic delays can persist for years, prolonging suffering and reducing quality of life. Amid this growing demand, Soligenix (NASDAQ: SNGX) is advancing a diversified pipeline of specialized biotherapeutics and public health solutions targeting rare and orphan conditions as it heads into 2026.

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the U.S. Food and Drug Administration through a Type C meeting, and advanced branding initiatives for AVERSA(TM) FENTANYL. Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study.

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in the brains of mice. This has created hope that the compound could, in future, be made into a pill that can treat glioblastoma, one of the deadliest forms of brain cancer.

In many over-the-counter (“OTC”) markets, capitalization structures are often diluted, and the incentives of management are misaligned, which may leave leadership unmotivated. However, Earth Science Tech (OTC: ETST), a strategic holding company, flips this idea on its head.

Scientists have found that keeping circadian rhythms, the variations in body processes during the course of the day, in mind while administering immunotherapy could hold the key to boosting treatment outcomes in patients with cancer.

The industrial world has officially crossed the Rubicon from experimental automation to autonomous humanoid labor. In a milestone that has sent ripples through both the automotive and artificial intelligence sectors, Figure AI has concluded its landmark deployment of the Figure 02 humanoid robot at the BMW Group (BMWYY) Plant Spartanburg. Over the course of a [...]